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INTRODUCTION
It is well established that people who inject drugs (PWID) are at the greatest risk of hepatitis C virus (HCV) infection. Globally, there are an estimated 16 million PWID who are currently injecting (Mathers et al., 2008) and of these, 10 million are estimated to have been infected with HCV (Nelson et al., 2011) . Chronic HCV infection is a major cause of liver-related morbidity and mortality but can be cleared with antiviral treatment and establishment of sustained viral response (SVR). Currently, there is low initiation of HCV antiviral treatment among PWID, which likely relates to concerns of adherence to and reinfection post-treatment (Martin et al., 2013; Iversen and Maher 2012) . Regardless, recent studies have indicated treatment outcomes to be acceptable and risk of HCV reinfection to be relatively low among PWID, albeit based on only a few small-scale studies conducted among selected populations in clinical and harm reduction settings often with limited follow-up (Aspinall et al., 2013; Arain and Robaeys, 2014; Grady et al., 2013) . Modelling work has further demonstrated that treating PWID is cost-effective and has the potential to reduce HCV transmission and prevalence in this population (Martin et al., 2011a (Martin et al., , 2013 . Therefore, recommendations state that treatment is not to be withheld from an individual based on injection status alone (EASL, 2015) .
After being deemed one of the greatest public health challenges of our time, HCV was made a priority by the Scottish Government and a comprehensive Action Plan was formulated to curb the predominately injecting-related epidemic (Chisholm, 2004; Scottish Government, 2008) . As a result, the overall number of people initiated on antiviral therapy in Scotland more than doubled between 2007 and 2010 with ~1000 now treated per year and the vast majority (>80%) of these report having ever injected drugs (HPA, 2013) .
Given this recent and anticipated future upscale in treatment provision among PWID a better understanding is needed of the injecting risk behaviours and potential for reinfection post-SVR. Our principal objective, therefore, was to establish evidence and predictors of continued engagement in injection drug use post-SVR using a record-linkage approach involving both HCV treatment and injecting-related hospitalisation data for a large nationally representative cohort of over 1000 PWID.
METHODS

Study Population, data sources, and linkage procedure
This paper utilised a retrospective cohort of Scottish PWID derived from the HCV Inclusion criteria for the study were a history of injection drug use, SVR attained by June, 2012, and sufficient identifiers for record-linkage. To enable further database linkage (described below), the HCV Clinical Database was first linked to the Scottish HCV Diagnosis Database, as previously described (Innes, et al., 2011) ; this linkage also allowed for scrutiny of patient record accuracy, such that patients were dropped if flaws in treatment records were detected (e.g., Mortality data were obtained through sourcing deaths registrations collated by National
Records of Scotland. Date and up to eleven causes of death are recorded for each registered death using ICD-9 and ICD-10 codes.
Linkage Procedure
ISD Scotland annually link the Scottish HCV Diagnosis Database to SMR and deaths data.
This probabilistic linkage technique is estimated to have a rate of false positives or false negatives under 5% (Kendrick and Clarke, 1993) ; the probabilistic linkage has also been previously described (McDonald et al., 2008) . 
Outcome Measures
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Our primary outcome was an injection-related hospitalisation (IRH) or death (IRD) post-SVR. We defined an injection-related cause based on ICD codes present in the primary or supplementary diagnostic position. Heroin has been and remains the predominant drug injected in Scotland (University of the West of Scotland, 2015), therefore the relevant outcome codes comprised opiate-related: mental and behavioural disorders due to opiate misuse (ICD-10: F11), poisoning due to opium (ICD-9: 965.0; ICD-10: T40.0), poisoning due to heroin (ICD-10:
T40.1), accidental poisoning due to heroin (ICD-9: E8500; ICD-10: X42.4), accidental poisoning due to opium (ICD-10: X42.9), intentional self-poisoning by exposure to opium (ICD-10: X62.9), opiate dependence (ICD-9: 3040), non-dependent opiate use (ICD-9: 3055), finding opiates in blood (ICD-10: R781), and injection-related as defined in previous literature: endocarditis (ICD-9: 421.0; ICD-10: I33), deep vein thrombosis (ICD-9: 451, 453 ; ICD-10: I80), cellulitis /abscesses (ICD-9: 682; ICD-10: L02, L03) (Lloyd-Smith et al., 2008; Irish et al., 2007) .
Explanatory variables
Behavioural and demographic exposure variables of interest were recorded for each patient pre-SVR and were obtained from clinical and SMR records.
Behavioural variables included presence of an acute alcohol intoxication-related hospital episode, and history of an IRH pre-SVR (using the above listed codes). Alcohol intoxication-related hospital episodes have been previously defined and include hospital episodes due to problems related to lifestyle alcohol use (ICD-10: Z72.1), mental and behavioural disorders due to use of alcohol (ICD-10: F10), toxic effect of alcohol (ethanol, methanol, unspecified) (ICD-9: 980.0, 980.1, 980.9; ICD-10: T51.0, T51.1, T51.9), blood alcohol level 100-240+/ 100 ml (ICD-9: 790.3; ICD-10: Y90.5 -Y90.9), evidence of alcohol involvement determined by level of intent (ICD-10: Y91), finding of alcohol in blood (ICD-10: R78.0), poisoning by and exposure to alcohol (ICD-9: E8600-02, E8609; ICD-10: X45, X65, Y15), alcohol deterrents (ICD-10: Y57.3), alcohol abuse counselling and surveillance (ICD-10: Z71.4), non-dependent alcohol abuse (ICD-9: 305.0).
Additional explanatory variables for each PWID included age at SVR, gender, year of SVR (date of SVR was defined as negative HCV RNA reading 24 weeks post-treatment completion), and presence of cirrhosis at treatment initiation. Age at SVR was categorised into three groups (<30, 30-44, ≥45). Year of SVR was categorised for descriptive analysis (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) and kept continuous for statistical modelling. Patients who were cirrhotic at time of treatment initiation were identified by the Clinical Database based on a combination of (i) clinical examination, (ii) radiology (ultrasound, transient elastography, computed tomography, Page 6 of 21 A c c e p t e d M a n u s c r i p t or magnetic resonance imaging), or (iii) liver biopsy, as previously described (Innes, et al., 2012) .
Statistical Analyses
All statistical analyses, data storage, and manipulation were conducted using STATA version 12 (College Station, TX, USA). years is illustrated in Figure 1 .
Analysis
RESULTS
Sample Characteristics (Table 1)
First-time opiate or injection-related hospital episode post-SVR
The overall crude rate of our outcome post-SVR was 3.12 per 100 PY (Table 2) , with the highest incidence rate noted in PWID who had an IRH pre-SVR (6.04 per 100 PY). Within the respective exposure variable groups, those aged 30 or younger at SVR had the highest incidence All covariates, with the exception of gender and cirrhosis, were associated with our outcome in univariate analysis (Table 2 ). Significant independent predictors of an IRH or IRD post-SVR identified in multivariate Cox regression include: year of SVR (AHR: 1.07, 95% CI, 1.01 -1.14), history of alcohol intoxication-related hospital episode pre-SVR (AHR: 1.83, 95% CI 1.29 -2.60), and history of IRH pre-SVR (AHR: 2.59, 95% CI 1.84 -3.64). Age at SVR did not retain its significance after adjusting for covariates.
Multiple opiate and injection-related hospital episodes post-SVR
Among 1170 PWID followed from SVR attainment, we observed a total of 225 injectionrelated hospital episodes and 11 deaths due to an injection-related cause. Thus there were a total of 149 first-time admissions/deaths and a further 87 subsequent readmissions/deaths following first IRH; the latter 87 readmissions/deaths related to 48 PWID with up to 8 events A c c e p t e d M a n u s c r i p t observed per PWID (Table 3) . In univariate analysis, all factors with the exception of cirrhosis at treatment initiation were associated with incidence of IRH and/or IRD post-SVR. Female gender (adjusted incidence rate ratio [AIRR]: 1.32, 95% CI 1.00 -1.73), history of alcohol intoxication-related hospital episode pre-SVR (AIRR: 2.95, 95% CI 2.24 -3.89), and history of IRH pre-SVR (AIRR: 2.59, 95% CI 1.99 -3.36) retained their significance in the multivariate model.
DISCUSSION
With highly effective but costly HCV treatments on the horizon and potential demand for treatment to increase particularly among the population who injects drugs, it is essential that the behaviours which pose a risk of reinfection post-SVR are well understood. There have been few small-scale studies examining engagement in injection drug use post-HCV antiviral treatment induced SVR. These studies rely on participation, accurate self-report by PWID, and have varied in respect of recruitment setting; thus, rates of continued injection drug use ranged considerably from 33% to 100% post-SVR (Dalgard, 2005; Grebely et al., 2009; Page et al., 2009) . Results obtained from our study were derived from a large anonymous record-linkage exercise of routine administrative data on all PWID undergoing therapy, thereby increasing cohort size and avoiding participation bias.
This study estimated that 10.6% of the Scottish cohort of 1170 PWID (i.e., those known to have acquired their infection through injecting drug use) had been in hospital for or had died from an injection-related cause in the first three years post-SVR. This compared to a greater proportion (19%) of the cohort who had an IRH in the three years prior to treatment initiation, which is consistent with recent evidence, also from Scotland, suggesting that patients attaining SVR lead healthier lives (Innes et al., 2015) . A minority of people who actively inject drugs likely end up in hospital or die from an injection-related cause each year. For example, a survey in England recently found 13% of 1058 people who were actively injecting drugs had been admitted to hospital with an injection site infection in the last year (Hope et al., 2008) . Further, a Canadian study found that approximately 26% of active PWID, recruited through street outreach, had been admitted to hospital (for any cause) in the previous six months (Palepu et al., 1999) . Given this context, it is then plausible that a greater proportion of our cohortpotentially several-fold higher than the 10.6% reported here within three years of SVR -were injecting drugs during the early years following successful therapy.
A relatively low risk of HCV reinfection post-SVR has so far been reported from studies involving PWID (pooled rate of 2 per 100 PY from recent meta-analysis), with risk of HCV reinfection greater among those reporting actively injecting drugs (6 per 100PY); however Page 9 of 21 A c c e p t e d M a n u s c r i p t these were predominately centred in settings with considerable harm reduction and clinical support and thus may not reflect the wider injecting population (Aspinall et al., 2013) Additional analysis considering multiple events per patient yielded similar predictors, but also highlighted a significantly increased rate among females versus males. Female gender was an independent predictor of multiple injection-related hospitalisations post-SVR, a finding corroborating previous research (Palepu et al., 2011) . It is hypothesized that this significant disparity in incidence between males and females could be due to many reasons including gender-related differences in care seeking behaviour.
Individuals found to have been hospitalised for either an IRH or alcohol intoxicationrelated cause prior to antiviral therapy initiation, being 30% of our cohort, were at significantly increased risk of both single and multiple IRH and/or IRD post-SVR. Likewise, those younger compared to older in age, although not significant in multivariate analysis, were more likely to engage in injecting practices post-successful treatment, as indicated by an estimated 15% and 7% of those aged under 30 and over 45 years, respectively, having been in hospital or died from an injection-related cause within three years of SVR attainment. This hospitalisation data may then help target a group who are particularly prone to re-engaging with risk behaviours.
There are some limitations to our study. Using hospital records will most likely underrepresent injecting frequency post-SVR. Hospitalisations represent extreme injecting outcomes (e.g., poisoning, overdose, severe injury), and thus likely underestimate the extent to which PWID are continuing to engage in injecting drugs post-successful treatment. Additionally, utilising hospital records relies on ICD codes as a measure of current-diagnosis. ICD codes indicating opiate use or injection drug use will not always necessarily indicate acute injecting episodes and could thus include historical events or non-injecting opiate abuse, both of which could have caused an overestimation of the true rate of hospitalisation for post-SVR injection drug use. Our analysis of multiple events did not exclude time spent in hospital and thus that Page 10 of 21 A c c e p t e d M a n u s c r i p t may have weakened the strength of association with some covariates, compared to that observed in the primary analysis of first-time IRH or IRD; further follow-up is required to fully assess the extent of readmission/death in this cohort.
This study did not explore engagement in additional risk factors of HCV reinfection (e.g., tattooing, sexual practices) post-SVR, although these are unlikely to pose the same population risk as continued injecting drug use. Further, we did not consider specifically the risk of reinfection here, as it required follow-up laboratory data on HCV RNA testing, but this is now the focus of a subsequent study. This risk behaviour research has, however, informed the need to fully understand the extent of testing and diagnosis of PWID post-SVR. Additionally, SVR patients account for roughly 60% of the overall treated population, and we therefore did not report on the behaviours of remaining 40% who were treated and did not attain the optimal outcome, leaving scope for further research using such a comparison group (Innes, et al., 2012) .
Implications and Recommendations
Treatment induced viral clearance is well known to improve health outcomes, yet it does not completely remove the risk of liver-related morbidity and mortality. Lifestyle factorsthat can either accelerate the rate of liver disease progression (e.g., alcohol consumption) or cause re-infection pose a significant excess risk of liver disease among patients who have attained SVR (Innes et al., 2013) . This study indicates that the risk of HCV reinfection post-SVR might increase as treatment is expanded and scaled up among injecting populations.
Treatment regiments that are highly effective, reduced in toxicity, and shorter in duration are at the forefront of current HCV research and care. The benefits of such treatments offer greater opportunity to scale up therapy among this population who inject drugs than ever before. Modelling studies have further illustrated the potential to reduce and control HCV transmission among PWID through such a treatment-to-prevent approach (Martin et al., 2011b (Martin et al., , 2013 . Our findings highlight that for patients who successfully complete treatment and would ordinarily be discharged from care, continued monitoring with RNA testing would be advised for those with on-going risk behaviour, in line with European guidelines (EASL, 2015) . Harm 
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